BiotechTube

LPCN 1154A + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Depression, Postpartum

Conditions

Depression, Postpartum, Depression, Post-Partum, Postpartum Depression (PPD), Post-Natal Depression, Peripartum Depression, Postnatal Depression

Trial Timeline

Jun 16, 2025 → Feb 17, 2026

NCT ID
NCT06979544

About LPCN 1154A + Placebo

LPCN 1154A + Placebo is a phase 3 stage product being developed by Lipocine for Depression, Postpartum. The current trial status is completed. This product is registered under clinical trial identifier NCT06979544. Target conditions include Depression, Postpartum, Depression, Post-Partum, Postpartum Depression (PPD).

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06979544Phase 3Completed

Competing Products

20 competing products in Depression, Postpartum

See all competitors
ProductCompanyStageHype Score
Olanzapine and Fluoxetine combination (OFC) + FluoxetineEli LillyPhase 3
77
DuloxetineEli LillyApproved
85
FK949EAstellas PharmaPhase 3
77
QuetiapineAstellas PharmaPre-clinical
23
duloxetine + escitalopram + placeboEli LillyPhase 3
77
duloxetineEli LillyApproved
85
Duloxetine HydrochlorideEli LillyPhase 3
77
DuloxetineEli LillyApproved
85
DuloxetineEli LillyApproved
85
Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)Eli LillyApproved
85
Duloxetine + PlaceboEli LillyPhase 3
77
DuloxetineEli LillyApproved
85
duloxetine + fluoxetine + citalopram + paroxetine + sertralineEli LillyApproved
85
Olanzapine + PlaceboEli LillyPhase 3
77
Olanzapine + Fluoxetine + PlaceboEli LillyPhase 3
77
duloxetine + duloxetineEli LillyPre-clinical
23
olanzapine + ziprasidoneEli LillyApproved
85
Olanzapine Fluoxetine Combination (OFC) + PlaceboEli LillyApproved
85
Drug treatment with CymbaltaEli LillyApproved
85
DuloxetineEli LillyApproved
85

Other Products from Lipocine

LPCN 1021Phase 3
69
LPCN 1021Phase 3
69
Oral testosterone undecanoate, LPCN 1021 + Topical testosterone gel 1.62 %Phase 3
69
LPCN 1021Phase 3
69
LPCN 1144Phase 2
44